UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identification No. ...

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2019 Earnings Conference Call May 7, 2019 4:45 PM ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Vincent Capponi - COO Kathleen Bloch - CFO Eric Mortensen - Chief Medical Officer Christian Steiner - SVP of Sales and Marketing Christopher Cramer - VP of Business Development Conference Call Participants Andrew D'Silva - B. Riley FBR Jason McCarthy - Maxim Group Brian Marckx - Zacks Investment Research Operator Good aftern ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identification No ...

CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q4 2018 and Full Year 2018 Earnings Conference Call March 7, 2019 Conference Call Participants Vincent Capponi, MS Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Dr. Eric Mortensen, MD, PhD Chief Medical Officer Dr. Christian Steiner, MD Vice President of Sales and Marketing 2 Dr. Phillip Chan, MD, PhD Chief Executive Officer and President Chris Cramer, MS, MBA Vice President of Business Development Mod ...

Cytosorbents Corp (NASDAQ:CTSO) Q4 2018 Earnings Conference Call March 7, 2019 4:45 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Phillip Chan - Chief Executive Officer and President Kathleen Bloch - Chief Financial Officer Vincent Capponi - Chief Operating Officer Christopher Cramer - Vice President of Business Development Christian Steiner - Vice President of Sales and Marketing Eric Mortensen - Chief Medical Officer Conference Call Participants Joshua Jennings - Cowen & ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of incorporation or (I.R.S. Emp ...

HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE | --- | --- | --- | --- | |-------|-------|--------------|----------------------------------------------------------------| | | | | | | | | NASDAQ: CTSO | Dr. Phillip Chan, MD, PhD - CEO BIO CEO & Investor Conference | Safe Harbor Statement This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, ...